Biotabs Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 M
- Revenue Growth 69.44%
- Profit Growth -148.29%
- Ebitda -653.81%
- Net Worth -48.62%
- Total Assets 18.18%
About Biotabs Lifesciences
Biotabs Lifesciences Private Limited (BLPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 December 2012 and has a history of 12 years and two months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.20 M.
Nachiappan Manimuthu, Harishbabu Lakshmanan, and Thilagavathi Durairaj serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85100TN2012PTC088940
-
Company No.
088940
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Dec 2012
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Biotabs Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nachiappan Manimuthu
|
Director | 24-Jun-2015 | Current |
|
Harishbabu Lakshmanan
|
Director | 01-Mar-2022 | Current |
|
Thilagavathi Durairaj
|
Director | 15-Jan-2024 | Current |
Financial Performance of Biotabs Lifesciences.
Biotabs Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 69.44% increase. The company also saw a substantial fall in profitability, with a 148.29% decrease in profit. The company's net worth observed a substantial decline by a decrease of 48.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biotabs Lifesciences?
In 2022, Biotabs Lifesciences had a promoter holding of 65.13% and a public holding of 34.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.20 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Nov 2019 | Others | ₹1.20 M | Open |
How Many Employees Work at Biotabs Lifesciences?
Unlock and access historical data on people associated with Biotabs Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biotabs Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biotabs Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
